Ultragenyx Pharmaceutical Inc. $RARE Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 74.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 51,637 shares of the biopharmaceutical company’s stock after purchasing an additional 21,958 shares during the quarter. Hsbc Holdings PLC’s holdings in Ultragenyx Pharmaceutical were worth $1,080,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the third quarter valued at approximately $39,000. Leonteq Securities AG raised its stake in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $56,000. Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 43.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 751 shares in the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Ultragenyx Pharmaceutical by 26.1% during the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 549 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RARE. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Wedbush decreased their price objective on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Morgan Stanley increased their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Finally, Cantor Fitzgerald boosted their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $58.41.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total transaction of $144,188.80. Following the sale, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. The trade was a 17.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the sale, the director directly owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 19,319 shares of company stock valued at $476,837 in the last 90 days. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Trading Down 3.4%

NASDAQ:RARE opened at $25.98 on Wednesday. The stock has a 50 day moving average of $27.57 and a two-hundred day moving average of $24.70. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $39.89. The firm has a market cap of $2.56 billion, a P/E ratio of -4.25 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The firm had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business’s revenue was down 2.2% compared to the same quarter last year. During the same quarter last year, the business earned ($1.57) EPS. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.